Guggenheim reiterates Buy on EyePoint stock, cites trial progress By Investing.com

Guggenheim reiterated a Buy on EyePoint with a $68 price target versus a $13.35 share price, citing continued progress in wet AMD and DME trials and no safety signals in Phase III data. Enrollment is complete in LUGANO and LUCIA, with topline wet AMD data expected starting mid-2026 and DME topline data in Q4 2027, while $223 million in cash supports a runway into Q4 2027. Offseting the bullish trial update, EyePoint also reported a Q1 2026 EPS miss of -$0.99 vs. -$0.82 expected and revenue of $0.7 million vs. $1.01 million forecast.

Analysis

The market is still pricing EYPT like a binary trial story, but the hidden lever is duration: with cash runway stretching into the same window as the key wet AMD readout, dilution risk is no longer the main overhang unless the company accelerates spending or data slip. That shifts the equity from a pure funding trade to a data-quality trade, where each quarter of clean safety updates should compress the financing discount and widen the base of holders that can own the name.

The bigger second-order effect is competitive, not clinical. If the safety profile continues to hold while dosing convenience and durability remain intact, EYPT can force attention away from crowded anti-VEGF incumbents toward a differentiated long-acting maintenance format, which matters most in retina where switching costs are high but physician inertia is even higher. That creates asymmetric pressure on smaller adjacent programs with weaker safety or less runway, because investors will likely re-rate the best-capitalized platform first.

The contrarian read is that the stock may already be discounting a meaningful probability of success after a 119% run; the next leg likely requires either stronger-than-expected efficacy or a faster regulatory path than the market currently assumes. Near term, the risk is not just trial failure but any wobble in enrollment pace or an adverse safety event that would re-open the dilution narrative and hit the multiple hard. In other words, the setup is favorable over months, but the next few weeks are mostly about not giving back credibility.

Key Decisions for Investors

• Stay long EYPT into the next safety-data update, but size it as a catalyst position rather than a core hold; the setup favors another rerating if clean data continues, while the downside is limited by balance-sheet support over the next 12-18 months.
• Buy EYPT call spreads targeting the mid-2026 readout window; risk/reward is attractive if the market starts to price in NDA optionality, with defined downside versus stock.
• Use any 10-15% post-rally pullback in EYPT to add exposure; avoid chasing strength because the stock likely needs either data validation or a broader biotech risk-on tape to sustain multiples.
• Pair EYPT long against a weaker, earlier-stage retina/ophthalmology name with less cash runway and less advanced data; the long should outperform on de-risking while the short carries higher dilution and trial-failure risk.
• If a safety signal appears or enrollment guidance slips, cut exposure quickly rather than averaging down; the thesis depends on credibility, and that would reintroduce financing overhang almost immediately.